Climb Bio (CLYM) Other Non-Current Liabilities (2020 - 2023)

Climb Bio (CLYM) posted Other Non-Current Liabilities of $22000.0 for Q4 2023, down 35.29% on a QoQ basis from $34000.0 in Q3 2023.

Climb Bio (CLYM) Other Non-Current Liabilities (2020 - 2023) Analysis & Trends

Climb Bio's Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $22000.0 for Q4 2023.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $22000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $22000.0 (changed N/A YoY) and the FY2023 annual result came in at $22000.0, changed N/A from the prior year.
Other Non-Current Liabilities was $22000.0 for Q4 2023 at Climb Bio, down from $34000.0 in the prior quarter.
Across five years, Other Non-Current Liabilities topped out at $551000.0 in Q4 2020 and bottomed at $7000.0 in Q4 2021.
A 3-year average of $126000.0 and a median of $44500.0 in 2023 frame the typical range for Other Non-Current Liabilities.
Peak annual rise in Other Non-Current Liabilities reached 98.73% in 2021, while the deepest fall reached 98.73% in 2021.
Climb Bio's Other Non-Current Liabilities stood at $551000.0 in 2020, then sank by 98.73% to $7000.0 in 2021, then surged by 214.29% to $22000.0 in 2023.
Business Quant data shows CLYM's Other Non-Current Liabilities at $22000.0 in Q4 2023, $34000.0 in Q3 2023, and $55000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Climb Bio	870.33 Mn	870.33 Mn	-

Download Data